Search

Your search keyword '"Mansfield, A.S."' showing total 16 results
Start Over Author "Mansfield, A.S." Publication Year Range Last 3 years
16 results on '"Mansfield, A.S."'

1. P2.16-03 RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer

Author

Mulvey, C., primary, Langdon, R., additional, Berilgen, J., additional, Chiappori, A., additional, Rineer, J.M., additional, Hao, Z., additional, Puri, S., additional, Parent, E., additional, Boike, T., additional, Rivera-Rodriguez, N., additional, Ferreira, D., additional, Li, J., additional, Ma, K., additional, Rearden, J., additional, Moran, S., additional, and Mansfield, A.S., additional

Published
2023
Full Text
View/download PDF

4. EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression

Author

Parikh, K., primary, Leventakos, K., additional, Mansfield, A.S., additional, Dimou, A., additional, Molina, J.R., additional, Ambrose, J., additional, Bai, C., additional, Hansen, E., additional, Barcellos, A., additional, Zettler, C., additional, Belli, A., additional, Fernandes, L., additional, and Wang, C.-K., additional

Published
2023
Full Text
View/download PDF

5. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Author

Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G., CHUV, Lausanne (Departement d'Oncologie), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Service de pneumologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Nord [CHU - APHM], Dicle University, Royal Cornwall Hospital, Service de Pneumologie [CHI Créteil], CHI Créteil, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, CRLCC René Gauducheau, Département d'oncologie médicale [Saint Herblain], UNICANCER-UNICANCER, Leiden University Medical Center (LUMC), Universiteit Leiden, Royal Marsden Hospital, Department of Energy and Process Engineering, Norwegian University of Science and Technology (NTNU), Bristol-Myers Squibb [Princeton], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Pulmonary Medicine

Subjects
Adult, PD-L1, [SDV]Life Sciences [q-bio], overall survival, Mesothelioma, Malignant, Hematology, Ipilimumab, Progression-Free Survival, immune checkpoint inhibitors, Nivolumab, Oncology, dual immunotherapy, Antineoplastic Combined Chemotherapy Protocols, Humans, CTLA-4, first-line
Abstract

International audience; Background: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of = 3 years after discontinuation. Conclusions: With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology.

Published
2022

6. Nivolumab (NIVO) plus ipilimumab (IPI) vs chimiothérapie (chimio) en traitement de première ligne du mésothéliome pleural malin (MPM) non résécable : résultats à 4 ans de l’étude CheckMate 743

Author

Zalcman, G., primary, Oulkhouir, Y., additional, Cornelissen, R., additional, Greillier, L., additional, Cid, J.R., additional, Mazières, J., additional, Briggs, P., additional, Nowak, A.K., additional, Tsao, A.S., additional, Fujimoto, N., additional, Peters, S., additional, Mansfield, A.S., additional, Popat, S., additional, Nassar, A., additional, Bushong, J., additional, Hu, N., additional, Spires, T.E., additional, Balli, D., additional, Eccles, L., additional, and Baas, P., additional

Published
2023
Full Text
View/download PDF

7. 125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (“PAVE”) in advanced non-small cell lung cancer (NSCLC) patients (pts)

Author

Imbimbo, M., primary, Ghisoni, E., additional, Mulvey, A., additional, Bouchaab, H., additional, Mederos Alfonso, N., additional, Karp, D., additional, Camidge, D.R., additional, Mansfield, A.S., additional, Yim, C.Y., additional, Ames, T.D., additional, Price, M., additional, Baeck, J., additional, O'Donnell, J.F., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

9. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Author

Griesinger, F., primary, Curigliano, G., additional, Thomas, M., additional, Subbiah, V., additional, Baik, C.S., additional, Tan, D.S.W., additional, Lee, D.H., additional, Misch, D., additional, Garralda, E., additional, Kim, D.-W., additional, van der Wekken, A.J., additional, Gainor, J.F., additional, Paz-Ares, L., additional, Liu, S.V., additional, Kalemkerian, G.P., additional, Houvras, Y., additional, Bowles, D.W., additional, Mansfield, A.S., additional, Lin, J.J., additional, Smoljanovic, V., additional, Rahman, A., additional, Kong, S., additional, Zalutskaya, A., additional, Louie-Gao, M., additional, Boral, A.L., additional, and Mazières, J., additional

Published
2022
Full Text
View/download PDF

11. 1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)

Author

Hu, M.I., primary, Subbiah, V., additional, Mansfield, A.S., additional, Taylor, M., additional, Schuler, M.H.H., additional, Zhu, V., additional, Hadoux, J., additional, Curigliano, G., additional, Wirth, L.J., additional, Garralda, E., additional, Adkins, D.R., additional, Godbert, Y., additional, Ahn, M-J., additional, Cassier, P.A., additional, Cho, B.C., additional, Lin, C-C., additional, Barata, T., additional, Zalutskaya, A., additional, Scalori, A., additional, and Brose, M.S., additional

Published
2022
Full Text
View/download PDF

12. LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Author

Zalcman, G., primary, Oulkhouir, Y., additional, Cornelissen, R., additional, Greillier, L., additional, Cid, J.R. Rodriguez, additional, Mazieres, J., additional, Briggs, P., additional, Nowak, A.K., additional, Tsao, A., additional, Fujimoto, N., additional, Peters, S., additional, Mansfield, A.S., additional, Popat, S., additional, Nassar, A., additional, Bushong, J., additional, Hu, N., additional, Spires, T., additional, Balli, D., additional, Eccles, L., additional, and Baas, P., additional

Published
2022
Full Text
View/download PDF

13. 1175P Predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated on the Pacific regimen

Author

Gao, R.W., primary, Prodduturvar, P., additional, Day, C.N., additional, Harmsen, W.S., additional, Olivier, K.R., additional, Merrell, K.W., additional, Garces, Y.I., additional, James, S., additional, McKone, T.K., additional, Ng, L., additional, Smith, R.S., additional, Stockham, A., additional, Wilson, Z., additional, Molina, J.R., additional, Leventakos, K., additional, Dimou, A., additional, Mansfield, A.S., additional, Amundson, A.C., additional, and Owen, D., additional

Published
2021
Full Text
View/download PDF

14. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Author

Peters, S., primary, Scherpereel, A., additional, Cornelissen, R., additional, Oulkhouir, Y., additional, Greillier, L., additional, Kaplan, M.A., additional, Talbot, T., additional, Monnet, I., additional, Hiret, S., additional, Baas, P., additional, Nowak, A.K., additional, Fujimoto, N., additional, Tsao, A.S., additional, Mansfield, A.S., additional, Popat, S., additional, Zhang, X., additional, Hu, N., additional, Balli, D., additional, Sanzari, J., additional, and Zalcman, G., additional

Published
2021
Full Text
View/download PDF

15. LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study

Author

Girard, N., Park, K., Tang, K., Cho, B.C., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J.W., Sabari, J.K., Sanborn, R.E., Mansfield, A.S., Hung, J-Y., Popat, S., Dias, J., Bhattacharya, A., Agrawal, T., Shreeve, M., Knoblauch, R.E., and Zhou, C.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results